KyungDong Pharm home
Prescription Medicines

Byaflu Cap.75mg

Product Category
antiviral drugs
Active Ingredients
Oseltamivir Phosphate
Appearance
A hard capsule with a light yellow cap and gray body, containing white or light yellow powder.
Reimbursement Code
648103920
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 capsule
- Active ingredient: Oseltamivir phosphate (USP)----98.5mg (75mg as oseltamivir)
- Additives: pregelatinized starch, capsule, croscarmellose sodium, talc, povidone, sodium stearyl fumarate

2. Effectiveness
1. Influenza A and influenza B virus infections in children and adults, including newborns over 2 weeks old (does not apply to children less than 36 weeks after conception) (administration must be started within 48 hours of the onset of initial symptoms of influenza infection).
2. Prevention of influenza A and influenza B virus infections in children over 1 year of age (the primary treatment for influenza virus infections is vaccination, so it is used only when the vaccine does not contain the relevant prevalent strains, when the effectiveness of the vaccine cannot be expected, or when vaccination is not possible. This drug cannot replace vaccination.)

3. Dosage and dosage
1. Influenza A and Influenza B virus infection: Start treatment on the first or second day when influenza symptoms appear. This drug can be administered regardless of food intake, and in some patients, tolerability may improve when taken with food.
1) Adults and youth over 13 years of age:
As oseltamivir, 75 mg is administered orally twice a day for 5 days. Adults and adolescents over 13 years of age who have difficulty swallowing capsules should use this drug suspension powder.
2) Children aged 1 to 12 years:
Pediatric patients who weigh more than 40 kg and are able to swallow capsules may take 75 mg capsules twice daily or 30 mg capsules and 45 mg capsules twice daily instead of the recommended dosage of this drug suspension.
Administer according to the following dosage table.

※ Table: Refer to attached document

3) Children over 2 weeks and under 1 year:
The recommended dose for pediatric patients aged 2 weeks to 12 months is 3 mg/kg orally twice a day for 5 days. It does not apply to children less than 36 weeks post-conception.
Administer according to the following dosage table*.

※ Table: Refer to attached document

* This table does not include all possible body weights for this patient group. Children under 1 year of age are recommended to take 3 mg/kg of this drug.
It is recommended that a pharmacist prepare the suspension before it is administered to the patient.
4) Patients with renal dysfunction
Patients with a creatinine clearance of 60 mL/min or more do not require dose adjustment, and patients with a creatinine clearance of 30 to 60 mL/min are recommended to reduce the dose to 30 mg twice a day for 5 days. For patients with a creatinine clearance of 10 to 30 mL/min, it is recommended to reduce the dose to 30 mg once a day for 5 days. Patients receiving periodic hemodialysis should administer a dose of 30 mg of this drug after each dialysis to maintain blood concentration in the therapeutic range, and the administration period should not exceed 5 days. If influenza symptoms occur during the 48 hours between dialysis sessions, it may be administered before starting dialysis. In the case of peritoneal dialysis, it is recommended to administer 30 mg of this drug as a single dose after dialysis. The pharmacokinetics of oseltamivir in patients with end-stage renal failure not on dialysis (e.g., creatinine clearance less than 10 mL/min) have not been studied, and therefore no dosage recommendations are provided for these patients.
5) Patients with liver dysfunction
No dose adjustment is necessary when treating adult patients with mild to moderate hepatic impairment (Child-Pugh score ≤ 9).

2. Prevention of influenza A and influenza B virus infections
1) Adults and youth over 13 years of age:
If you are in close contact with an infected person, administer 75 mg orally as oseltamivir once a day for 10 days. Begin administration within 2 days of contact with an infected person.
The recommended dose for prevention during an influenza epidemic is 75 mg once daily. The safety and effectiveness of this drug have been proven for up to 6 weeks. The preventive effect lasts while taking this drug.
2) Children aged 1 to 12 years:
Pediatric patients who weigh more than 40 kg and can swallow a capsule can take a 75 mg capsule once a day or a 30 mg capsule and a 45 mg capsule once a day for 10 days instead of the recommended dosage of this drug suspension.
Administer according to the following dosage table.

※ Table: Refer to attached document

It is recommended that a pharmacist prepare the suspension before it is administered to the patient.
※ The safety and effectiveness of preventing influenza A and B virus infections in children under 1 year of age have not been evaluated.
3) Patients with renal dysfunction
Patients with a creatinine clearance rate of 60 mL/min or more do not require dose adjustment, and patients with a creatinine clearance of 30 to 60 mL/min are recommended to reduce the dose to 30 mg once a day. For patients with a creatinine clearance of 10 to 30 mL/min, it is recommended to reduce the dose to 30 mg once a day and administer it every other day. Patients receiving periodic hemodialysis should receive a dose of 30 mg after every two dialysis sessions to maintain blood levels in the therapeutic range. The initial dose may be administered before starting dialysis. In the case of peritoneal dialysis, it is recommended to administer 30 mg of this drug once a week after dialysis. The pharmacokinetics of oseltamivir in patients with end-stage renal failure not receiving dialysis (e.g., creatinine clearance less than 10 mL/min) have not been studied, and therefore no dosage recommendations are provided for these patients.
4) Patients with liver dysfunction
No dose adjustment is necessary for prophylaxis in adult patients with mild to moderate hepatic impairment (Child-Pugh score ≤ 9).

4. Precautions for use
1. Warning
1) This medicine cannot replace influenza vaccination. There is no correlation between use of this drug and annual influenza vaccination. The preventive effect against influenza lasts only while using this drug. This drug is used for the treatment and prevention of influenza when there is reliable epidemiological data showing that the influenza virus is currently prevalent in the area.
2) The safety and effectiveness of this drug for treating infections other than influenza A and B have not been studied.
3) Among influenza patients taking this drug, neuropsychiatric adverse reactions such as convulsions and delirium were reported, mainly in children and adolescents. In rare cases, these adverse reactions have resulted in accidents. It is not known whether these adverse reactions are caused by administration of this drug, and these psychoneurological adverse reactions have also been reported in patients who did not take this drug.
In particular, pediatric and adolescent patients should be closely monitored for abnormal behavior.
Although the causal relationship is unclear in pediatric patients over 10 years of age, cases of abnormal behavior and accidents such as falls after taking this drug have been reported, mainly in Japan. For this reason, in principle, this drug should not be used in patients in this age group, except in cases where they are judged to be high risk due to complications or past medical history.
To prevent accidents in children and adolescents, it should be explained to patients and their families that there is a risk of abnormal behavior occurring after treatment with this drug begins and that guardians should be careful not to leave children or adolescents alone for at least 2 days when receiving treatment at home.
In addition, there are reports that the same symptoms appear due to influenza encephalopathy, etc., so the explanation should be the same as above.

2. Do not administer to the following patients.
Patients with hypersensitivity to this drug or its components

3. Administer with caution to the following patients.
1) Patients with renal failure
When administering this drug to patients with moderate (patients with a creatinine clearance rate of 30 to 60 mL/min) and severe (patients with a creatinine clearance rate of 10 to 30 mL/min) renal failure, hemodialysis or peritoneal dialysis patients, dosage adjustment is required (see Dosage and Administration section). This drug is not recommended for patients with end-stage renal failure who are not receiving dialysis (e.g., creatinine clearance less than 10 ml/min). There are no data on the safety and effectiveness of this drug in pediatric patients with renal failure.
2) High-risk group patients (asthma, chronic bronchitis, immunosuppression) (experience of use is very rare)

4. Adverse reactions
The overall safety of this drug was evaluated based on the results of clinical trials in more than 2,647 adults/adolescents and 858 pediatric patients infected with influenza, and more than 1,945 adults/adolescents and 148 children who were administered this drug for the purpose of preventing influenza. The most frequently reported adverse drug reactions during treatment studies in adults/adolescents were nausea, vomiting, and headache. Most of these adverse drug reactions were one-time, occurring on the first or second day of administration and resolved within 1 to 2 days. The most frequently reported adverse drug reactions during prevention studies in adults/adolescents were nausea, vomiting, headache, and pain. The most frequently reported adverse drug reaction in children was vomiting. In most patients, these adverse drug reactions did not reach the point where they had to stop taking the drug.
1) Influenza treatment and prevention in adults/adolescents: Influenza treatment and prevention studies in adults/adolescents most frequently occurred (more than 1%) at the recommended dose (treatment: 75 mg twice a day for 5 days, prevention: 75 mg once a day for up to 6 weeks). Adverse drug reactions with an incidence rate of more than 1% higher than the placebo group were nausea, vomiting, headache and It was painful (see Table 1). The influenza treatment study targeted healthy adults/adolescents and high-risk patients (patients at risk of influenza complications, i.e., elderly people and patients with chronic heart disease or respiratory disease). In general, the safety profile in high-risk patients was qualitatively similar to that in healthy adults/adolescents. Despite the longer duration of drug administration, the safety profile reported in the prevention study (75 mg once daily for up to 6 weeks) was qualitatively similar to that observed in the treatment study (Table 1).
2) Adverse reactions occurring in less than 1% of patients taking this drug included unstable angina, anemia, pseudomembranous colitis, pneumonia, peritonsillar abscess, humerus fracture, hallucinations, convulsions, dermatitis, rash, urticaria, and eczema.
3) Influenza treatment and prevention in the elderly: There was no clinically meaningful difference in the safety profile of 942 elderly patients administered this drug or placebo compared with younger people (age 65 or younger).

※ Table 1: Refer to attached document

* Adverse drug reactions occurred 1% more frequently than placebo when administering this drug
The frequency of adverse reactions in the group administered this drug is presented in the table above, and the frequency is defined as very frequent (≥1/10) and frequent (≥1/100, <1/10).

4) Clinically significant adverse reactions
Although the frequency of occurrence is not clear, additional adverse reactions that may occur due to administration of this drug are as follows.
(1) Shock and anaphylactic reactions: Shock and anaphylactic reactions may occur, and patients should be carefully observed. If symptoms such as urticaria, facial and laryngeal edema, difficulty breathing, or decreased blood pressure appear, administration should be discontinued and appropriate measures should be taken.
(2) Pneumonia: Pneumonia has been reported to occur. If abnormalities are observed, the cause (e.g., drugs, infection) should be determined through radiological examination and appropriate methods.
(3) Hepatitis, abnormal liver function, and jaundice: Hepatitis, abnormal liver function, and jaundice accompanied by a significant increase in AST, ALT, γ-GTP, and ALP may occur. Patients should be observed carefully, and if abnormalities occur, administration should be discontinued and appropriate measures should be taken.
(4) Skin abnormalities such as mucocutaneous ocular syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome): Skin abnormalities such as mucocutaneous ocular syndrome (Stevens-Johnson syndrome) and toxic epidermal necrolysis (Riel syndrome) may occur. Patients should be observed carefully, and if these symptoms occur, administration should be discontinued and appropriate measures should be taken.
(5) Acute renal failure: Acute renal failure may occur. Patients should be observed carefully, and if such abnormalities are observed, administration should be discontinued immediately and appropriate measures should be taken.
(6) Decrease in white blood cells and platelets: Decrease in white blood cells and platelets may occur. Patients should be observed carefully, and if such abnormalities are observed, appropriate measures, such as discontinuation of treatment, should be taken.
(7) Psychoneurological syndrome: Psychoneurological symptoms (disordered consciousness, abnormal behavior, delirium, hallucinations, delusions, convulsions) may appear. If abnormalities are observed, administration should be discontinued. Patients should be carefully observed and appropriate measures should be taken according to each symptom.
(8) Hemorrhagic colitis: Hemorrhagic colitis may occur. If abnormalities such as bloody stool are observed, administration should be discontinued and appropriate measures should be taken to the patient.
5) Other adverse reactions
Other adverse reactions reported after administration of this drug are as follows. If such adverse reactions are confirmed, appropriate measures such as discontinuation of administration are taken depending on the symptoms.

※ Table 2: Refer to attached document

*) Spontaneous reports whose frequency cannot be calculated were classified as frequency unknown.

6) Influenza treatment and prevention in children over 1 year of age: Among 1,480 pediatric patients (healthy children aged 1 to 12 years and asthma patients aged 6 to 12 years) who participated in influenza treatment clinical trials, a total of 858 patients received this drug suspension. The adverse reaction that occurred in more than 1% of children aged 1 to 12 years who were naturally infected with influenza and was administered this drug for treatment (n = 858), with an incidence of more than 1% compared to placebo (n = 622), was vomiting (16% in the drug-treated group and 8% in the placebo group). In a home post-exposure prophylaxis study (n = 99) and a separate 6-week pediatric prophylaxis study (n = 49), the most common adverse reaction among 148 children administered the recommended dose once daily was vomiting (8% in the group receiving this drug and 2% in the group not receiving prophylaxis). In the above clinical trials, this drug was well tolerated and the reported adverse reactions were consistent with those observed in previous pediatric treatment studies.

※ Table 3: Refer to attached document

7) During the pediatric influenza treatment study, adverse reactions that occurred in less than 1% of cases when administering this drug included lymphadenitis (<1% of the drug-treated group, 1% of the placebo-treated group) and eardrum abnormalities (<1% of the drug-treated group, 1% of the placebo-treated group).
8) Data on children over 2 weeks old and under 1 year old
The evaluation of adverse events is based on two open label studies. This study includes safety data when 135 influenza-infected children aged 2 weeks to less than 1 year (including premature infants with a gestational age of 36 weeks or more) were exposed to 2 to 3.5 mg/kg of body weight twice daily for 5 days. The safety profile was similar across the age range studied, with vomiting, diarrhea and diaper rash being the most commonly reported adverse reactions. The safety profile observed in children aged 2 weeks to less than 1 year was consistent with that established for adults and adolescents aged 1 year and older.
9) Prevention of influenza in patients with immune disorders
475 patients with immune disorders (including 18 pediatric patients) participated in a clinical trial for influenza prevention. In adolescents and adults with immune disorders aged 13 years or older who received this drug for 12 weeks for prevention during the influenza epidemic period, adverse reactions were the same as those observed in existing prevention studies.
10) Post-marketing experience
The following adverse reactions have been reported after marketing this drug: Because the following adverse reactions were voluntarily reported in unknown populations, it is difficult to establish their frequency and/or relationship to this drug.
(1) Skin and subcutaneous tissue: Hypersensitivity reactions such as dermatitis, rash, eczema, urticaria, erythema multiforme, allergy, anaphylaxis or anaphylactoid reaction, facial edema, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome) have been reported.
(2) Liver and biliary system: Hepatitis, elevated liver enzyme levels, and liver failure have been reported.
(3) Cardiovascular system: arrhythmia
(4) Mental nervous system: seizures, confusion
(5) Gastrointestinal system: gastrointestinal bleeding, hemorrhagic colitis
(6) Metabolism: Diabetes worsening
(7) Blood: eosinophilia, leukopenia
(8) Others: Pancreatitis, angioedema, laryngeal edema, tongue edema, bronchospasm, facial edema, hematuria, etc. have been reported.
(9) In general, influenza and high fever are associated with severe neuropsychiatric disorders such as insomnia, confusion, convulsions, and hallucinations in some cases even when this drug is not administered. These adverse reactions have been reported after marketing of this drug, but a relationship with the drug has not been established.
11) As a result of a use result survey conducted on 3,130 people over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 0.93% (29 cases/3,130 cases) regardless of causal relationship, and among these, 0.67% (21 cases/3,130 cases) were found to have a causal relationship with this drug. Nausea was the most common with 12 cases, followed by vomiting in 4 cases and diarrhea in 2 cases. In addition, abdominal pain, nightmares, dizziness, and dermatitis were reported in 1 case each.
12) As a result of analysis and evaluation of clue information based on domestic post-marketing adverse event reporting data (1989-June 2016), the newly confirmed adverse cases are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
- Mental system: Sleep disorder

5. General precautions
1) This drug is not a substitute for the influenza vaccine. Use of this medicine should not affect influenza vaccination according to guidelines from the Center for Disease Controls Prevention Advisory Committee on Immunization Practices.
2) No treatment information has been provided for patients who are at risk or in a very bad condition requiring hospitalization. Additionally, there has been no research on the safety and effectiveness of repeating the treatment process. There is no experience of administering this drug for more than 6 weeks in phase 3 clinical studies for the treatment of influenza.
3) Safety has been confirmed for administration for up to 12 weeks for prevention during the influenza epidemic in patients with immune disorders. The effectiveness of this drug for the treatment and prevention of influenza in patients with immune disorders has not been clearly established.
4) The effectiveness of this drug in patients who started treatment 40 hours after symptom onset has not been established.
5) Severe bacterial infections may begin with influenza-like symptoms and may co-exist with influenza or occur as a complication during the course of influenza. This medicine cannot prevent these complications.
6) The effectiveness of this drug for patients with chronic heart disease or respiratory disease has not been established. When this drug and placebo were administered to these groups, no difference in the incidence of complications was observed between the drug and placebo groups.
7) Patients should be instructed to use this medication as early as possible in flu symptoms. If you fail to take the medicine on time, you must take the missed dose as soon as possible and at a certain time thereafter, unless the interval between the next scheduled time is less than 2 hours.
8) Although no effects were observed on driving a car or operating machinery, the possibility of damage to these abilities due to influenza should be kept in mind.

6. Interaction
1) As a result of pharmacological and pharmacokinetic tests of this drug, it is expected that there will be no clinically significant drug interactions.
2) This drug is rapidly converted to the active form by esterase mainly present in the liver. Drug interactions based on competition for esterases are rarely reported in the literature. The protein binding rate between this drug and the active form is low, so the possibility of drug-substitute interaction is slim. According to in vitro experiments, both this drug and its active metabolite are not affected by CYP-450 mixed-function oxidase or glucuronyl transferase, so it is believed that there is no drug interaction related to CYP-450 isoenzymes.
3) Drugs involved in competitive renal tubular secretion are unlikely to have clinically significant interactions due to their safety margin, excretion characteristics of active metabolites (glomerular filtration and anionic tubular secretion), and excretory properties. However, drugs with a narrow safety margin that involves active renal excretion (e.g., chlorpropamide, methotrexate, phenylbutazone) should be used with caution when administered together.
4) There is no basis for interaction with oral contraceptives in terms of mechanism of action.
5) Cimetidine, known to alter gastric acidity, is a non-specific inhibitor of CYP-450 isoenzymes and competes with basic or cationic drugs for renal tubular secretion. Cimetidine does not affect plasma concentrations of this drug or its active metabolite. Therefore, clinically significant drug interactions are not expected with drugs that alter gastric acidity (antacids) or drugs that are excreted through the same metabolic pathway, and interactions with antacids have not been tested in vivo.
6) As a result of combined use of probenecid, the systemic availability of active metabolites increased approximately two-fold due to a decrease in active renal tubular secretion, but there was no need to adjust the dose because the safety margin was wide.
7) When used together with amoxicillin, the plasma concentrations of each other did not change. This means that it has little competition in the anionic excretion pathway and is unlikely to compete significantly with other organic acids (e.g. aspirin) that are excreted through the renal tubules.
8) Even when used in combination with acetaminophen, the plasma concentrations of this drug, its active metabolite, and acetaminophen did not change.
9) After co-administration of this drug (75 mg, administered twice a day for 4 days) and 900 mg of aspirin, there were no significant changes in the active metabolite of this drug and the pharmacokinetic parameters of aspirin.
10) After co-administration of this drug with antacids containing aluminum hydroxide and magnesium hydroxide or antacids containing calcium carbonate, acetaminophen, aspirin, cimetidine, warfarin, and rimantadine, there were no significant changes in the pharmacokinetic parameters of this drug and its active metabolites.
11) Interaction with ganciclovir, whose substrate is secreted into the renal tubules, has been reported post-marketing.
12) In phase Ⅲ clinical trials, this drug was tested against ACE inhibitors (enalapril, captopril), thiazide diuretics (bendrofluazide), antibiotics (penicillin, cephalosporin, azithromycin, erythromycin, doxycycline), H2 receptor blockers (ranitidine, cimetidine), beta blockers (propranolol), Even when administered together with commonly used drugs such as xanthines (theophylline), sympathomimetics (pseudoephedrine), opiates (codeine), corticosteroids, inhaled bronchodilators, and analgesics (aspirin, ibuprofen, acetaminophen), there was no change in the type or frequency of adverse reactions.
13) Influenza vaccine: Simultaneous use of this drug with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Because of potential interference between these agents, LAIV should not be administered within 2 weeks before or 48 hours after administration of this drug, except in medically proven cases. There is increasing consideration of potential interference with antiviral drugs that inhibit replication of live vaccine viruses. Trivalent inactivated influenza vaccine can be administered at any time in conjunction with use of this drug.

7. Administration to pregnant and lactating women
1) In pre- and postnatal development and maternal function tests, when 1,500 mg/kg/day was administered to rats, delivery time was delayed and the number of births decreased on the 4th day after birth. As a result of reproductive toxicity tests on rats and rabbits, no malformations were observed. As a result of fertility and reproductive performance experiments in rats, no effect on fertility was found at all doses tested.
2) In rats and rabbits, drug exposure to the fetus was approximately 15 to 20% compared to maternal exposure. Currently, there is insufficient data on pregnant women taking this drug to determine whether this drug has the potential to cause fetal malformations or fetal toxicity. Therefore, when this drug is used in pregnant women or women who may be pregnant, the therapeutic benefits must outweigh the risks.
3) There are no clinical studies on the use of this drug in pregnant women, but there is limited research through post-marketing surveillance and observational study reports. Analysis of this data combined with animal testing showed no direct or indirect adverse effects on pregnancy, embryo/fetus, or postnatal development. This drug can be administered after considering safety information, pathogenicity of the prevalent influenza virus strain, and the condition of the pregnant woman.
4) In lactating rats, this drug and its active metabolite were secreted into milk. From animal test data, it is predicted that this drug will be secreted at about 0.01 mg/day and the active metabolite form at about 0.3 mg/day. There is very limited information on whether this drug can be detected in breast milk or in infants who ingest the breast milk of nursing mothers who have taken this drug. These limited data indicate that this drug and its active metabolite are excreted in breast milk, but in small amounts and at subtherapeutic doses. Considering this information, the pathogenicity of the prevalent influenza virus strain, and the condition of the nursing mother, if the obvious therapeutic benefits outweigh the risks, administration of this drug to nursing mothers can be considered.

8. Administration to children
The effectiveness of this drug in children under 1 year of age has not been established. According to pharmacokinetic data, when 3 mg/kg of this drug was administered twice a day to children aged 2 weeks to 12 months, blood concentrations of prodrugs and active metabolites expected to be clinically effective were shown, and the safety profile was equivalent to that of children aged 1 year and older and adults. The safety and effectiveness of this drug in newborns less than 2 weeks of age have not been studied for the treatment of influenza, and the safety and effectiveness of this drug in children less than 1 year of age have not been studied in the prevention of influenza.

9. Administration to elderly people
Clinical data in the elderly are limited, but considering drug exposure and tolerability, no dose adjustment is necessary. Elderly people often have reduced physical functions (renal function, liver function, etc.) and are prone to suffering from various chronic diseases, so patients should be carefully observed when administering this drug.

10. Treatment in case of overdose
Cases of overdose have been reported in clinical trials and post-marketing experience, and in most cases, no adverse reactions were reported. The adverse reactions reported after overdose were similar in type and frequency to the adverse reactions when this drug was administered at the prescribed dosage (see Adverse Reactions section).

11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

12. Pharmaceutical equivalence test information
A. The test drug Oseltamivir Phosphate Capsule 75 mg (KyungDong Pharm Co., Ltd.) and the reference drug Tamiflu Capsule 75 mg (Roche Korea Co., Ltd.) were administered orally once, 1 capsule each, to 46 healthy adults in a 2×2 crossover test. As a result, oseltamivir in the blood was measured. When the comparative evaluation item values (AUCt, Cmax) were log-transformed and statistically processed, the average value was The 90% confidence interval of the difference was within log 0.8 to log 1.25, demonstrating biological equivalence.
※ Table: Refer to attached document

13. Others
1) In a phase Ⅲ clinical study on influenza prevention in Japan, one case of worsening diabetes was reported, and in a phase Ⅲ clinical study on influenza prevention conducted overseas, 7 cases of worsening diabetes or hyperglycemia were reported in patients with glucose metabolism disorders. However, no inhibition of glucose metabolism was observed in non-clinical tests administered at 100 times the clinical dose.
2) Virus resistance
① The possibility of developing influenza viruses with resistance or reduced sensitivity to oseltamivir was evaluated through clinical trials. All cases of oseltamivir-resistant virus carriers were transient, the virus was cleared normally, and no worsening of baseline symptoms was observed.

※ Table: Refer to attached document

*Full genotyping was not performed in all trials.
In clinical trials conducted on immunocompetent patients for post-exposure (7 days), household contacts post-exposure (10 days), and seasonal influenza prevention (42 days), there was no evidence of development of drug resistance related to Tamiflu administration. No tolerance was observed during the 12-week prophylaxis trial in immunocompromised patients.
② Natural mutations associated with reduced susceptibility to oseltamivir were observed in vitro in influenza A and B isolates from patients who had never been exposed to oseltamivir. In Europe in 2008, the H275Y substitution, associated with oseltamivir resistance, was found in more than 99% of circulating H1N1 influenza. In contrast, 2009 H1N1 influenza (“swine flu”) was almost uniformly sensitive to oseltamivir. Resistant strains were isolated from both immunocompetent and immunocompromised patients treated with oseltamivir. The prevalence of sensitive and resistant viruses to oseltamivir varies seasonally and geographically. Additionally, oseltamivir resistance has been reported during treatment and prophylaxis in patients with pandemic H1N1 influenza.
The incidence of resistance may be high in immunocompromised patients and children under 12 years of age. Oseltamivir-resistant viruses isolated from patients receiving oseltamivir and laboratory strains of oseltamivir-resistant influenza viruses were observed to contain N1 and N2 neuraminidase mutations. Resistance mutations tend to be virus sub-type specific.
Prescribers should consider the influenza virus drug susceptibility pattern for each season when deciding to prescribe Tamiflu.


5. How to save
Airtight container, stored below 25℃

6. Packaging unit
10 capsules/PTP

7. Period of use
36 months from date of manufacture

Product Updates

Total 2items

No.Product NameDetailsDate of ChangeDownload
2Byaflu Cap.75mgPrecautions for use2024.09.03PDF0058_201702624_Precautions for use (Villaflu Capsule).pdf
1Byaflu Cap.75mgVillaflu Capsule 75mg (Precautions for use...2017.08.22HWPChanges_Villaflu Capsule 75mg.hwp